Eton Pharmaceutcials, Inc. (ETON) Dividend History

Eton Pharmaceuticals, Inc. (ETON) is a specialty pharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. It aims to provide innovative solutions for underserved patient populations through the development of injectable, oral, and topical formulations. The company leverages its expertise in formulation development and regulatory affairs to bring new treatments to market.

21925 W. Field Parkway, Deer Park, IL, 60010-7278
Phone: (847) 787-7361
Website:

Dividend History

Eton Pharmaceutcials, Inc. currently does not pay dividends

Company News

  • Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

    •  Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth•  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400•  Management to hold conference call today at 4:30pm ET

    GlobeNewswire Inc.
  • Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

    DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:

    GlobeNewswire Inc.
  • Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

    - Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product has patent protection through 2043 -

    GlobeNewswire Inc.
  • Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

    DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

    GlobeNewswire Inc.
  • Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

    DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. rights to PKU GOLIKE® from RELIEF THERAPEUTICS Holding SA (“Relief”) (SIX: RLF, OTCQB: RLFTF, RLFTY).

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 08:29:04 UTC